Reuters logo
2 months ago
BRIEF-Soligenix says presenting final results from SGX942 Phase 2 clinical trial at MASCC
June 19, 2017 / 10:14 AM / 2 months ago

BRIEF-Soligenix says presenting final results from SGX942 Phase 2 clinical trial at MASCC

June 19 (Reuters) - Soligenix Inc:

* Complete efficacy and long-term follow-up safety results from SGX942 phase 2 oral mucositis clinical trial to be presented at the 2017 multinational association for supportive care in cancer conference

* Soligenix- On basis of results, received FDA clearance, EMA scientific advice on, pivotal Phase 3 clinical trial, to be initiated in 2017 for SGX942 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below